Dose-Dense Chemo Shows Promise as Neoadjuvant Therapy in Bladder Cancer
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - May 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Source Type: news

Nodal Response to Pre-Op Tx Tied to Survival in Esophageal Cancer
WEDNESDAY, May 2, 2018 -- For patients with locally advanced esophageal cancer, the status of lymph nodes following preoperative neoadjuvant chemotherapy or chemoradiation therapy determines survival, according to a study presented at the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 2, 2018 Category: Pharmaceuticals Source Type: news

For patients with esophageal cancer, status of lymph nodes after preoperative therapy determines survival
(American Association for Thoracic Surgery) The status of lymph nodes rather than the status of the primary tumor following preoperative neoadjuvant chemotherapy or chemoradiation therapy is the most important factor that determines whether patients with locally advanced esophageal cancer will survive. The study presented at the AATS 98th Annual Meeting indicates that while preoperative chemotherapy and radiation therapy improve survival of patients with esophageal cancer, patients with malignant lymph nodes following therapy were less likely to survive than patients with no cancer in the lymph nodes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2018 Category: Cancer & Oncology Source Type: news

Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy Improved Rectal-Cancer Survival Seen With Adjuvant Chemotherapy
Adjuvant chemotherapy is associated with improved overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the potential role of immune checkpoint inhibitors in the neoadjuvant setting may be the most promising.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Neoadjuvant Nivolumab Yields High Response in Newly Diagnosed NSCLC
Neoadjuvant nivolumab combo proved safe while yielding high response rates in patients with NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes Circulating Tumor Cell Count Predicts Early Breast Cancer Outcomes
Circulating tumor cell (CTC) count independently predicts outcomes in women with early breast cancer treated with neoadjuvant chemotherapy, according to a meta-analysis.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 24, 2018 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery Improved Pancreatic Survival Seen After Neoadjuvant Therapy and Surgery
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Neoadjuvant Anti-PD-1 Active in Multiple Tumors (CME/CE)
(MedPage Today) -- Major responses in pilot study for NSCLC, melanoma, bladder cancers (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 18, 2018 Category: Dermatology Source Type: news

Neoadjuvant Nivolumab Shows Benefit in NSCLC Neoadjuvant Nivolumab Shows Benefit in NSCLC
Already used for nonresectable lung cancer, immunotherapy is now heading for the neoadjuvant niche, with nivolumab showing benefit when used before surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

TNT Is Viable for Locally Advanced Rectal Cancer
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - April 6, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news

Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer Total Neoadjuvant Approach Promising in Locally Advanced Rectal Cancer
Preoperative chemotherapy in combination with chemoradiation (total neoadjuvant therapy, or TNT) appears to have advantages over traditional approaches to treating locally advanced rectal cancer, according to new research.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2018 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Some HER2+ Breast Cancer Patients Could Avoid SLNB Following Neoadjuvant Therapy
Two new studies have found that some HER2-positive and triple-negative breast cancer patients can avoid sentinel lymph node biopsy after neoadjuvant systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Triple-Negative Breast Cancer Source Type: news

Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer Carboplatin in Neoadjuvant Chemo May Be Helpful in Triple-negative Breast Cancer
Carboplatin should be considered as a potential component of neoadjuvant chemotherapy for women with high-risk, triple-negative breast cancer, regardless of BRCA status, researchers suggest.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 19, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Biomarkers to Predict Treatment Response in Bladder Cancer Biomarkers to Predict Treatment Response in Bladder Cancer
A new study looks at whether certain biomarkers may predict response to adjuvant and neoadjuvant treatments for bladder cancer.Translational Andrology and Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2018 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Neoadjuvant Therapy Controls High-Risk Melanoma (CME/CE)
(MedPage Today) -- Trial of targeted combination stopped early (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 30, 2018 Category: Dermatology Source Type: news

More Intense Neoadjuvant ECX Regimen Fails for Esophageal Cancer More Intense Neoadjuvant ECX Regimen Fails for Esophageal Cancer
Dr Kerr reports on a large, well-designed trial with disappointing results.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Rethinking neoadjuvant chemotherapy for breast cancer
This BMJ analysis notes that neoadjuvant chemotherapy may not be beneficial to patients as increased pathological response of primary tumour does not translate into a survival benefit. It suggests that the widespread use of neoadjuvant chemotherapy should be reduced. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 12, 2018 Category: Consumer Health News Source Type: news

Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer Neoadjuvant Chemotherapy Tied to Better Survival in Advanced Ovarian Cancer
The adoption of neoadjuvant chemotherapy is associated with reduced mortality in women with advanced epithelial ovarian cancer, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Neoadjuvant Chemotherapy Tied to Improved Ovarian Cancer Survival
In women with advanced ovarian cancer, increased use of neoadjuvant chemotherapy (NACT) followed by surgery — rather than primary cytoreductive surgery — is associated with reduced mortality... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 5, 2018 Category: Primary Care Source Type: news

Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer
Ongoing clinical trials are evaluating aggressive chemotherapy regimens and radiotherapy in pancreatic cancer.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Radiotherapy of Early-Stage Breast Cancer Neoadjuvant Radiotherapy of Early-Stage Breast Cancer
Does neoadjuvant radiotherapy improve overall survival in women with early-stage breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer? Why Is Neoadjuvant Endocrine Therapy Underused in Breast Cancer?
Experts discuss the evidence behind neoadjuvant endocrine therapy for early-stage breast cancer and obstacles to wider use of this treatment strategy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Contrast-enhanced digital mammography comparable to breast MRI after therapy or chemo
(Mayo Clinic) Contrast-enhanced digital mammography is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy, according to the results of a study presented by Mayo Clinic researchers today at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2017 Category: Cancer & Oncology Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Chemoradiotherapy Remains Standard of Care in Cervical Cancer Chemoradiotherapy Remains Standard of Care in Cervical Cancer
Chemoradiotherapy remains the standard of care for cervical cancer patients with locally advanced disease, concludes an Indian trial that compared it to neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response ass...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Study confirms chemoradiation is best treatment for locally advanced cervical cancer
(European Society for Medical Oncology) A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings are reported today at the ESMO 2017 Congress in Madrid. The trial demonstrated no improved disease-free survival with neoadjuvant chemotherapy followed by surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2017 Category: Cancer & Oncology Source Type: news

CT Abnormality in Patient With Stage II Breast Cancer History
A 57-year-old woman with a history of stage IIB breast cancer (ypT2N1M0) status post neoadjuvant chemotherapy and left partial mastectomy presents to the radiation oncology clinic for CT simulation in preparation for breast radiotherapy. Noncontrast CT scan incidentally found the abnormality depicted with arrows below. (Source: CancerNetwork)
Source: CancerNetwork - September 8, 2017 Category: Cancer & Oncology Authors: Joseph Miccio, MD Tags: Image IQ Source Type: news

Cynvenio and Saint Luke ’s Cancer Institute Launch Pilot Study to...
New Study will use LiquidBiopsy® ClearID® testing and NK Score™ natural killer cell activity testing to monitor breast cancer patients following neoadjuvant chemotherapy.(PRWeb August 17, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14601181.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 17, 2017 Category: Pharmaceuticals Source Type: news

Urothelial Cancer Response to Neoadjuvant Chemo Varies by Histologic Variant
Certain histologic variants of urothelial bladder cancer benefit more from neoadjuvant chemotherapy, according to a new study. (Source: CancerNetwork)
Source: CancerNetwork - August 3, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Bladder Cancer Genitourinary Cancers News Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

Radiation prior to surgery reduces risk of secondary tumors in early-stage breast cancer
(H. Lee Moffitt Cancer Center& Research Institute) Moffitt researchers found that patients who have neoadjuvant radiation therapy have a significantly lower risk of developing a second primary tumor at any site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 17, 2017 Category: Cancer & Oncology Source Type: news

T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)
(MedPage Today) -- 41% of HER2+/HR+ patients achieved a pathologic complete response (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 16, 2017 Category: Hematology Source Type: news

Rectal Cancer Response to Preop Tx Doesn't Rule Out Nodal Disease Rectal Cancer Response to Preop Tx Doesn't Rule Out Nodal Disease
Rectal cancer patients who have a complete clinical response (ypT0) to neoadjuvant chemoradiation (NCR) may still have nodal disease, according to new research.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Role of Neoadjuvant Therapy in Pancreatic Cancer'Unproven'Role of Neoadjuvant Therapy in Pancreatic Cancer'Unproven '
Despite a growing body of evidence, neoadjuvant therapy still cannot be recommended as standard treatment in patients with borderline resectable pancreatic cancer, says an expert in the field.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Chemo Prior to CRT in Nasopharyngeal Carcinoma May Improve Outcomes
The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Head & Neck Cancer News Source Type: news

Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer
The data are early and the cohort small, but use in the neoadjuvant and adjuvant setting showed antitumor activity.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many TNBC Patients Unnecessarily Opt for Mastectomy
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Breast Cancer News Triple-Negative Breast Cancer Source Type: news

COUNTERPOINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
In a Significant Percentage of Patients, Neoadjuvant Therapy Yields Equivalent Survival, With Better Quality of Life and Lower Costs (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Authors: Anna Fagotti, MD, PhD Giovanni Scambia, MD Tags: Gynecologic Cancers Oncology Journal Ovarian Cancer Source Type: news

POINT: Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer
Cytoreductive Surgery Is the Best Way to Affect Survival Outcomes (Source: CancerNetwork)
Source: CancerNetwork - June 15, 2017 Category: Cancer & Oncology Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer
Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Ovarian Cancer News Source Type: news

U.S. women with triple-negative breast cancer treated with neoadjuvant therapy are far more likely to choose mastectomies than women overseas
findings were released online ahead of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 2-6, 2017 (Source: BWH News)
Source: BWH News - June 2, 2017 Category: Hospital Management Source Type: news

Treatment of Low-Lying Early Rectal Cancer
This video examines the treatment of patients with low-lying rectal cancer and explores options such as neoadjuvant chemoradiotherapy, which could improve the efficacy of surgery. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2017 Category: Cancer & Oncology Authors: Julio Garcia-Aguilar, MD, PhD Tags: Videos Gastrointestinal Cancers Source Type: news

Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation Watch-and-Wait for Some Rectal Cancer Patients After Chemoradiation
Among patients with locally advanced rectal cancer who have a clinical complete response to neoadjuvant chemoradiation, most will not experience tumor regrowth and may avoid radical surgery when a wait-and-watch approach is used, new research suggests.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 22, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Dateline City: KENILWORTH, N.J. Now Approved for First-Line Treatment in Patients Ineligible for Cisplatin-Containing Chemotherapy and Second-Line Treatment in Patients Who Have Disease Progression During or Following Platinum-Containing Chemotherapy or Within 12 Months of Neoadjuvant or Adjuvant Treatment with Platinum-Containing Chemotherapy KEYTRUDA is the Only Anti-PD-1 Therapy to Demonstrate Superior Overall Survival Versus Chemotherapy in Patients With Advanced Urothelial Carcinoma Post-Platinum FailureKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,...
Source: Merck.com - Product News - May 18, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news

New VTE Often Occurs During Chemo in Ovarian Cancer
Most cases of venous thromboembolism occurred during neoadjuvant or adjuvant chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 11, 2017 Category: Cancer & Oncology Tags: Cardiology, Gynecology, Nursing, Oncology, Surgery, Journal, Source Type: news